Clinical trial
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of…
NCT00233441 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00233441 |
|---|---|
| Title | Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter |
| Official title | Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter |
| Acronym | MAIA |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Atrial Flutter |
| Intervention type | Drug |
| Interventions | CELIVARONE (SSR149744C) |
| Enrollment | 673 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Oct 5, 2005 |
| Last update posted | May 8, 2012 |
| Countries | Argentina, Australia, Canada, Chile, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Poland and 5 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: